INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Abstract Background Pediatric patients with relapsed or refractory disease represent a population with a desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to translate next generation molecular diagnostics into a biomarker driven...

Full description

Bibliographic Details
Main Authors: Cornelis M. van Tilburg, Ruth Witt, Melanie Heiss, Kristian W. Pajtler, Christoph Plass, Isabel Poschke, Michael Platten, Inga Harting, Oliver Sedlaczek, Angelika Freitag, David Meyrath, Lenka Taylor, Gnana Prakash Balasubramanian, Natalie Jäger, Elke Pfaff, Barbara C. Jones, Till Milde, Stefan M. Pfister, David T. W. Jones, Annette Kopp-Schneider, Olaf Witt
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Cancer
Subjects:
Entinostat
Nivolumab
Child
Bayesian design
Biomarker
Phase I/II
Online Access:http://link.springer.com/article/10.1186/s12885-020-07008-8

Internet

http://link.springer.com/article/10.1186/s12885-020-07008-8

Similar Items